

Calculating an NAFCS score¹

Fill in values for each category below and add category scores to determine the NAFCS score and help facilitate a diagnosis of FCS. This calculator should only be used for use in patients ≥ 1 year old with hypertriglyceridemia (≥ 440 mg/dL). In patients ≥ 10 years old, the calculator is intended for patients who are not responsive to fibrates and high-dose omega-3 fatty acids even when the patient is adherent to therapy (ie, triglycerides do not decrease by 20% or more from these treatments and do not remain reduced). The NAFCS Score does not provide a value for pregnant patients.

Current Age (Calculator cannot be used for patients <1 year old) *

$\geq 1-9$ [+12]

≥ 10 [+0]

HTG onset (years)	<10 [+12]
(Only ask of patients ≥ 10)	≥ 10 [+0]

Points are assigned only for either age $\geq 1-9$ or age ≥ 10 . Not both.

Body Mass Index (percentile for children/adolescents) *

<25 kg/m² or <85th percentile [+9]

≥ 25 kg/m² or $\geq 85^{\text{th}}$ percentile [+0]

History of Pancreatitis *

Pancreatitis [+16]

Abdominal pain but no pancreatitis [+9]

Neither abdominal pain nor pancreatitis [+0]

Presence of secondary factors[†] that may contribute to hypertriglyceridemia *

None [+11]

1 or more secondary factors [+0]

Laboratory Values (Select all that apply)

All triglycerides >880 mg/dL [+13]

Ratio triglycerides/total cholesterol >8[‡] [+8]

Apolipoprotein B (apoB) <1.0 g/L [+12]

Additional Points Added (Select all that apply)

If patient is $\geq 1-9$ years old AND has no secondary factors [+7]

If triglycerides/total cholesterol >8[‡] AND apoB <1.0 g/L [+7]

If triglycerides/total cholesterol >8[‡] AND has no secondary factors [+5]

Interpreting Results

≥ 60 strongly indicates definite FCS

$\geq 45-59$ likely FCS

$\geq 30-44$ genetic testing should be considered in these patients

<30 deems unlikely FCS, but genetic testing may still be needed

Total Score

Adapted from Hegele et al. *J Clin Lipidol*. Published online November 12, 2024. doi:10.1016/j.jacl.2024.09.008¹

If infant presents with no secondary factors that may contribute to hypertriglyceridemia, consider a diagnosis of FCS. If infant presents with ≥ 1 secondary factor that may contribute to hypertriglyceridemia, but with 2 triglyceride readings >880 mg/dL and unexplained failure to thrive, consider a diagnosis

of FCS.¹ †See second page for complete list of secondary factors.² ‡When measured in mg/dL.¹ FCS, familial chylomicronemia syndrome; NAFCS North American familial chylomicronemia syndrome.

MED-US--2500243 v2 06/2025

Secondary factors that may contribute to hypertriglyceridemia²

	Adolescents/adults	Children	Infants
Lifestyle	• High alcohol intake • Reduced physical activity • High fat or sugar intake • Ultraprocessed (NOVA4) food diet	• High fat or sugar intake • Ultraprocessed (NOVA4) food diet	
Clinical conditions	• Autoimmune chylomicronemia (eg, systemic lupus erythematosus, anti-lipoprotein lipase antibodies) • Uncontrolled diabetes type 1 or 2 (non-pancreatitis induced) • Endocrine causes (eg, Cushing's syndrome, polycystic ovarian syndrome, growth hormone deficiency, acromegaly) • Human immunodeficiency virus (HIV) • Hypothyroidism • Metabolic syndrome • Rare genetic disorders (eg, glycogen storage disorders) • Lipodystrophies • Renal causes (eg, chronic renal failure, nephrotic syndrome) • Glycerol kinase deficiency • Autoantibodies against GPI-HDL binding protein 1	• Cancer • Congenital nephrotic syndrome • Glycogen storage disease type 1 • Hypothyroidism • Protein-losing enteropathy • Lipodystrophies • Glycerol kinase deficiency	• Cancer • Congenital nephrotic syndrome • Hypothyroidism • Protein-losing enteropathy • Glycerol kinase deficiency
Medications	• Androgen deprivation therapy • Antidepressants (eg, sertraline) • Antiretrovirals (eg, protease inhibitors) • Atypical antipsychotics • Beta-adrenergic blocking agents • Bile acid binding resins • Diuretics • Estrogen, estrogen receptor agonists, estrogen receptor modulators, oral contraceptives • Glucocorticoids (eg, corticosteroids) • Immunosuppressants (eg, cyclosporine) • L-asparaginase • Propofol • Retinoids, retinoid X receptor agonists • Total parenteral nutrition	• Total parenteral nutrition • Glucocorticoids (eg, corticosteroids) • Chemotherapy • Antiretrovirals (eg, protease inhibitors) • Immunosuppressants (eg, cyclosporine) • Propofol • For older children: — Antidepressants (eg, sertraline) — Atypical antipsychotics	• Total parenteral nutrition • Glucocorticoids (eg, corticosteroids) • Chemotherapy

Adapted from Hegele et al. *J Clin Lipidol*. Published online November 12, 2024 (online-only supplementary material). doi: 10.1016/j.jacl.2024.09.008²

The information is intended as educational information for healthcare professionals. It does not replace a healthcare professional's judgment or clinical diagnosis.

References: 1. Hegele RA, Ahmad Z, Ashraf A, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. *J Clin Lipidol*. Published online November 12, 2024. doi:10.1016/j.jacl.2024.09.008 2. Hegele RA, Ahmad Z, Ashraf A, et al. Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America. *J Clin Lipidol*. Published online November 12, 2024 (online-only supplementary material). doi:10.1016/j.jacl.2024.09.008